Opaleye Management
Latest statistics and disclosures from Opaleye Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are HROW, TGTX, SLRN, RYTM, OCUL, and represent 44.64% of Opaleye Management's stock portfolio.
- Added to shares of these 10 stocks: ARVN (+$11M), ARQT (+$6.3M), CDXS (+$5.9M), TGTX (+$5.6M), RLMD, Jasper Therapeutics, NTLA, NAMS, VTYX, SYRS.
- Started 13 new stock positions in ARVN, ARQT, Jasper Therapeutics, CNTX, NAMS, FULC, PTGX, STRO, KNSA, VTYX. NTLA, SYRS, ALGS.
- Reduced shares in these 10 stocks: MOR (-$11M), BHVN (-$10M), TELA (-$6.0M), KALV, GERN, CRNX, IGMS, RYTM, EWTX, OCUL.
- Sold out of its positions in Fortress Biotech, GERN, IGMS, KZR, TELA, TCON, XERS.
- Opaleye Management was a net buyer of stock by $6.9M.
- Opaleye Management has $373M in assets under management (AUM), dropping by 22.38%.
- Central Index Key (CIK): 0001595855
Tip: Access up to 7 years of quarterly data
Positions held by Opaleye Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Opaleye Management
Opaleye Management holds 46 positions in its portfolio as reported in the December 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Harrow Health (HROW) | 11.5 | $43M | 3.8M | 11.20 |
|
|
| Tg Therapeutics (TGTX) | 10.1 | $38M | +17% | 2.2M | 17.08 |
|
| Acelyrin (SLRN) | 8.3 | $31M | 4.1M | 7.46 |
|
|
| Rhythm Pharmaceuticals (RYTM) | 7.5 | $28M | -6% | 610k | 45.97 |
|
| Ocular Therapeutix (OCUL) | 7.3 | $27M | -6% | 6.1M | 4.46 |
|
| Catalyst Pharmaceutical Partners (CPRX) | 5.7 | $21M | +4% | 1.3M | 17.05 |
|
| Keros Therapeutics (KROS) | 3.8 | $14M | 358k | 39.76 |
|
|
| Ideaya Biosciences (IDYA) | 3.0 | $11M | 312k | 35.58 |
|
|
| Eton Pharmaceuticals (ETON) | 3.0 | $11M | +4% | 2.5M | 4.38 |
|
| Crinetics Pharmaceuticals In (CRNX) | 2.9 | $11M | -16% | 308k | 35.58 |
|
| Arvinas Ord (ARVN) | 2.9 | $11M | NEW | 264k | 41.16 |
|
| Codexis (CDXS) | 2.5 | $9.3M | +172% | 3.0M | 3.05 |
|
| Biohaven (BHVN) | 2.3 | $8.6M | -54% | 200k | 42.80 |
|
| Edgewise Therapeutics (EWTX) | 2.0 | $7.6M | -20% | 699k | 10.94 |
|
| Iovance Biotherapeutics (IOVA) | 2.0 | $7.3M | +47% | 897k | 8.13 |
|
| Arcutis Biotherapeutics (ARQT) | 1.7 | $6.3M | NEW | 2.0M | 3.23 |
|
| 4d Molecular Therapeutics In (FDMT) | 1.7 | $6.3M | 309k | 20.26 |
|
|
| Marinus Pharmaceuticals Com New (MRNS) | 1.6 | $6.1M | -3% | 564k | 10.87 |
|
| Vaxcyte (PCVX) | 1.5 | $5.7M | 90k | 62.80 |
|
|
| Liquidia Corporation Com New (LQDA) | 1.4 | $5.4M | -22% | 445k | 12.03 |
|
| Protara Therapeutics Com Stk (TARA) | 1.4 | $5.0M | 2.7M | 1.88 |
|
|
| Urogen Pharma (URGN) | 1.3 | $4.8M | 320k | 15.00 |
|
|
| Xoma Corp Del Com New (XOMA) | 1.2 | $4.6M | -8% | 250k | 18.50 |
|
| Applied Therapeutics (APLT) | 1.0 | $3.7M | +22% | 1.1M | 3.35 |
|
| Relmada Therapeutics (RLMD) | 1.0 | $3.6M | +2823% | 877k | 4.14 |
|
| Trevi Therapeutics (TRVI) | 0.9 | $3.4M | +48% | 2.5M | 1.34 |
|
| Jasper Therapeutics | 0.8 | $3.1M | NEW | 4.0M | 0.79 |
|
| Intellia Therapeutics (NTLA) | 0.8 | $3.0M | NEW | 99k | 30.49 |
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 0.8 | $3.0M | NEW | 265k | 11.17 |
|
| Gossamer Bio Note 5.000% 6/0 (Principal) | 0.8 | $2.9M | 8.0M | 0.36 |
|
|
| Larimar Therapeutics (LRMR) | 0.8 | $2.8M | -26% | 624k | 4.55 |
|
| Ventyx Biosciences (VTYX) | 0.8 | $2.8M | NEW | 1.1M | 2.47 |
|
| Syros Pharmaceuticals Com New (SYRS) | 0.7 | $2.8M | NEW | 359k | 7.79 |
|
| Gossamer Bio (GOSS) | 0.7 | $2.7M | -37% | 3.0M | 0.91 |
|
| Protagonist Therapeutics (PTGX) | 0.7 | $2.6M | NEW | 113k | 22.93 |
|
| Kalvista Pharmaceuticals (KALV) | 0.5 | $1.8M | -70% | 150k | 12.25 |
|
| Verastem Com New (VSTM) | 0.5 | $1.7M | 211k | 8.14 |
|
|
| Nyxoah S A SHS (NYXH) | 0.4 | $1.6M | -21% | 345k | 4.64 |
|
| Morphosys Sponsored Ads (MOR) | 0.4 | $1.4M | -88% | 145k | 9.90 |
|
| Precigen (PGEN) | 0.4 | $1.4M | +9% | 1.0M | 1.34 |
|
| Sutro Biopharma (STRO) | 0.3 | $1.3M | NEW | 302k | 4.29 |
|
| Context Therapeutics (CNTX) | 0.3 | $1.1M | NEW | 975k | 1.13 |
|
| Biodesix (BDSX) | 0.2 | $914k | +8% | 497k | 1.84 |
|
| Fulcrum Therapeutics (FULC) | 0.2 | $878k | NEW | 130k | 6.75 |
|
| Aligos Therapeutics (ALGS) | 0.2 | $861k | NEW | 1.3M | 0.66 |
|
| Kiniksa Pharmaceuticals Com Class A (KNSA) | 0.2 | $640k | NEW | 38k | 17.07 |
|
Past Filings by Opaleye Management
SEC 13F filings are viewable for Opaleye Management going back to 2013
- Opaleye Management 2023 Q4 filed Feb. 14, 2024
- Opaleye Management 2023 Q3 filed Nov. 15, 2023
- Opaleye Management 2023 Q2 filed Aug. 14, 2023
- Opaleye Management 2023 Q1 filed May 15, 2023
- Opaleye Management 2022 Q4 filed Feb. 10, 2023
- Opaleye Management 2022 Q3 filed Nov. 14, 2022
- Opaleye Management 2022 Q2 filed Aug. 15, 2022
- Opaleye Management 2022 Q1 filed May 16, 2022
- Opaleye Management 2021 Q4 filed Feb. 14, 2022
- Opaleye Management 2021 Q3 filed Nov. 16, 2021
- Opaleye Management 2021 Q2 filed Aug. 16, 2021
- Opaleye Management 2021 Q1 filed May 18, 2021
- Opaleye Management 2020 Q4 filed Feb. 12, 2021
- Opaleye Management 2020 Q3 filed Nov. 16, 2020
- Opaleye Management 2020 Q2 filed Aug. 14, 2020
- Opaleye Management 2020 Q1 filed May 15, 2020